Two G Protein Oncogenes in Human Endocrine Tumors

John F. Lyons(Institute of Human Genetics), Claudia A. Landis(University of California, San Francisco), Griffith Harsh(University of California, San Francisco), Lucia Vallar(San Raffaele University of Rome), Kurt Grünewald(Universität Innsbruck), Hans G. Feichtinger(Institute of Human Genetics), Quan‐Yang Duh(San Francisco VA Medical Center), Orlo H. Clark(San Francisco VA Medical Center), Ernest S. Kawasaki(Institute of Human Genetics), Henry R. Bourne(University of California, San Francisco), Frank McCormick(Adamas Pharmaceuticals (United States))
Science
August 10, 1990
Cited by 1,042

Abstract

Somatic mutations in a subset of growth hormone (GH)-secreting pituitary tumors convert the gene for the alpha polypeptide chain (alpha s) of Gs into a putative oncogene, termed gsp. These mutations, which activate alpha s by inhibiting its guanosine triphosphatase (GTPase) activity, are found in codons for either of two amino acids, each of which is completely conserved in all known G protein alpha chains. The likelihood that similar mutations would activate other G proteins prompted a survey of human tumors for mutations that replace either of these two amino acids in other G protein alpha chain genes. The first gene so far tested, which encodes the alpha chain of Gi2, showed mutations that replaced arginine-179 with either cysteine or histidine in 3 of 11 tumors of the adrenal cortex and 3 of 10 endocrine tumors of the ovary. The mutant alpha i2 gene is a putative oncogene, referred to as gip2. In addition, gsp mutations were found in 18 of 42 GH-secreting pituitary tumors and in an autonomously functioning thyroid adenoma. These findings suggest that human tumors may harbor oncogenic mutations in various G protein alpha chain genes.


Related Papers